iFlytek

iFlytek is a major Chinese artificial intelligence and speech recognition company, with a healthcare division that has deployed intelligent medical guidance robots and AI-assisted diagnosis systems across hundreds of hospitals nationwide per company reports. Spun off from the University of Science and Technology of China, the company has built broad AI healthcare solutions spanning patient navigation, clinical decision support, and medical imaging analysis.

Company Overview

Established in June 1999 by Liu Qingfeng during his doctoral studies at USTC, iFlytek pioneered commercial speech recognition technology in China. The company listed on the Shenzhen Stock Exchange in 2008 under stock code 002230, becoming the first publicly traded voice technology enterprise in China.

iFlytek entered the healthcare sector through its 2016 partnership with Anhui Provincial Hospital, establishing the Medical Artificial Intelligence Joint Laboratory. This collaboration produced China’s first AI-powered smart hospital in August 2017, demonstrating the integration of speech recognition, natural language processing, and medical knowledge graphs in clinical settings.

The healthcare business operates through iFlytek Healthcare Technology Co., Ltd., a subsidiary that filed for a Hong Kong IPO in January 2024. This unit focuses on clinical decision support systems, patient services, and medical devices including smart hearing aids.

Core Products

Xiaoyi Medical Guidance Robot

The Xiaoyi (晓医) robot serves as an intelligent navigation and triage assistant in hospital lobbies. Deployed at over 50 major hospitals including PLA General Hospital (301), Peking Union Medical College Hospital, and Shanghai Ruijin Hospital, Xiaoyi provides:

• Doctor scheduling information across 47+ departments
• Navigation to 618+ hospital locations
• Operating hours for 227+ service points
• Answers to 260+ common patient queries
• Symptom-based department recommendations

At Beijing 301 Hospital, Xiaoyi handles over 2,000 daily interactions, serving 600-700 patients per day.

Intelligent Medical Assistant

iFlytek’s Intelligent Medical Assistant achieved a historic milestone in November 2017 as the world’s first AI system to pass China’s National Medical Licensing Examination, scoring above 96.3% of human candidates. The system now operates in over 400 districts and counties across 30+ provinces, providing:

• Over 500 million assisted diagnostic suggestions
• Detection of 40+ million unnecessary prescriptions
• Diagnosis correction for 635,000 patients annually
• Coverage of 1,100+ diseases

Smart Medical Guidance System

The software-based guidance system extends Xiaoyi’s capabilities to digital platforms, covering 169 medical departments with support for 13,000+ symptoms and 5,200+ diseases. The system enables tiered diagnosis and patient routing aligned with China’s hierarchical healthcare policy.

iFlytek Xiaoyi App

Launched in October 2023 and powered by iFlytek’s Spark Medical Large Language Model, this mobile application offers seven core functions: symptom checking, medication queries, traditional Chinese medicine assessment, report interpretation, hospital recommendations, department guidance, and dietary suggestions.

Technology & Innovation

iFlytek’s healthcare AI builds on three core technology pillars developed over 25 years:

Speech Recognition: The company’s voice technology leads Chinese language processing, with medical-specific optimization covering 50+ clinical specialties and a vocabulary exceeding one million medical terms.

Medical Knowledge Graph: Built from 53 medical textbooks, 2 million de-identified electronic health records, and 400,000+ medical literature documents, this knowledge base powers clinical reasoning capabilities.

Cognitive AI: iFlytek’s systems have won international competitions in machine reading comprehension (SQuAD), common sense reasoning (Winograd Schema Challenge), and knowledge base population (NIST KBP), demonstrating advanced medical inference capabilities.

In August 2017, iFlytek set the world record in the LUNA medical imaging benchmark with a 94.1% average recall rate for lung nodule detection, demonstrating expertise in AI-assisted radiology.

Market Presence

iFlytek Healthcare serves multiple stakeholder groups across China’s medical ecosystem:

• Primary Healthcare: Intelligent Medical Assistant deployed in 400+ districts and counties
• Tertiary Hospitals: 400+ hospitals including 40 of China’s top 100
• Patient Services: Xiaoyi robot and app serving millions of users annually
• Regional Platforms: Anhui Province imaging cloud connecting 41 county hospitals

The company ranks first in China’s primary healthcare clinical decision support system (CDSS) market by revenue as of 2023.

Key Milestones

• 1999: Founded at University of Science and Technology of China
• 2008: Listed on Shenzhen Stock Exchange (002230.SZ)
• 2016: Established Medical AI Joint Laboratory with Anhui Provincial Hospital
• 2017: Launched Xiaoyi guidance robot; Intelligent Medical Assistant passed national medical exam
• 2017: China’s first AI smart hospital opened at Anhui Provincial Hospital
• 2023: Launched Xiaoyi App powered by Spark Medical Large Language Model
• 2024: iFlytek Healthcare filed for Hong Kong IPO
• 2024: Established global headquarters in Hong Kong with HK$400M investment plan

Frequently Asked Questions

What hospitals use iFlytek’s Xiaoyi robot?

Xiaoyi operates in over 50 major hospitals across China, including PLA General Hospital (301 Hospital), Peking Union Medical College Hospital, Shanghai Ruijin Hospital, and Anhui Provincial Hospital. The robot handles patient navigation, department scheduling queries, and preliminary symptom assessment.

Did iFlytek’s AI really pass the medical licensing exam?

Yes. In November 2017, iFlytek’s Intelligent Medical Assistant became the world’s first AI to pass China’s National Medical Licensing Examination (comprehensive written test), scoring 456 points against a passing threshold of 360, outperforming 96.3% of human candidates.

Is iFlytek Healthcare a separate company?

iFlytek Healthcare Technology Co., Ltd. operates as a subsidiary of iFlytek Co., Ltd. (002230.SZ). The healthcare unit filed for a Hong Kong IPO in January 2024 and focuses specifically on medical AI solutions, patient services, and medical devices.